Cytogenetics News and Research

RSS

Cytogenetics is a field of study that deals with chromosomes and related abnormalities. Chromosome analysis is also known as karyotyping and involves the pairing of homologous chromosomes.

YM BioSciences begins enrollment in CYT387 Phase II trial for myelofibrosis

YM BioSciences Inc. today announced that it has enrolled the first patients in its multi-center Phase II trial of CYT387 administered twice-daily (BID) for the treatment of myelofibrosis.

28 Sep 2011

Eisai's DACOGEN sNDA for acute myeloid leukemia accepted by FDA for review

SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced that Eisai Inc. today released information that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental New Drug Application (sNDA) seeking approval of DACOGEN (decitabine) for injection in the treatment of acute myeloid leukemia.

14 Jul 2011

FDA accepts Eisai's DACOGEN sNDA for review to treat acute myeloid leukemia

Eisai Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review its supplemental New Drug Application (sNDA) seeking approval of DACOGEN (decitabine) for injection in the treatment of acute myeloid leukemia.

13 Jul 2011

Cumulus cells can provide information about genetic and chromosomal status of eggs

At present, when a woman undergoes preimplantation genetic screening (PGS) in a fertility clinic, doctors are trying to select an egg or an embryo that is healthy and doesn't have a chromosome abnormality such as an extra copy of chromosome 21, which causes Down's syndrome. In order to establish this, they either have to biopsy a part of the egg called the polar body or remove a cell from the embryo for screening. Both procedures are expensive, invasive and can damage the egg or embryo.

6 Jul 2011

Start of clinical validation study of Down’s syndrome diagnostic test

In conjunction with several Central European prenatal centers, scientists at GATC Biotech AG and LifeCodexx AG have begun the clinical validation study of a non-invasive, prenatal diagnostic test based on next generation sequencing.

28 Jun 2011

Data from microarrays co-developed by OGT to be presented at ECC 2011

Oxford Gene Technology (OGT), provider of innovative clinical genetics and diagnostic solutions to advance molecular medicine, has announced details of its upcoming workshop at the European Cytogenetics Conference 2011, held in Porto, Portugal (2–5 July).

From Oxford Gene Technology 28 Jun 2011

AIS introduces Spectral karyotyping

AIS introduces Spectral karyotyping (SKY®) equipment, designed and manufactured by ASI, a leading developer of comprehensive solutions for pathology and cytogenetics. Spectral karyotyping (SKY®) is ASI’s novel addition to the cytogenetic tool kit. It is based on a unique electro-optical hardware that enables measuring the spectral image of a metaphase, previously stained, such that each chromosome class has a different color (created typically from different combinations of 5 or more basic dyes).

23 Jun 2011

Positive preliminary results from CytRx bafetinib Phase 2 trial for relapsed B-cell chronic lymphocytic leukemia

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that preliminary results from its ENABLE Phase 2 proof-of-concept trial demonstrated that bafetinib, the Company's Bcr-Abl, Lyn and Fyn kinase inhibitor, was clinically active in a group of patients with relapsed or refractory B-cell chronic lymphocytic leukemia (B-CLL) who have failed several other treatments for their cancer.

13 Jun 2011

Affymetrix reports total revenue of $73.7 million for first quarter 2011

Affymetrix, Inc., today reported its operating results for the first quarter of 2011. Total revenue for the quarter was $73.7 million, as compared to total revenue of $80.2 million in the first quarter of 2010.

28 Apr 2011

CSI's cancer cytogenetic testing receives COG approval

CSI Laboratories, a private national cancer diagnostics laboratory, has received approval from the Children's Oncology Group to begin analyzing pediatric cytogenetic cases. The Children's Oncology Group is the world's largest children's cancer research organization and includes more than 210 member hospitals with over 6,500 medical professionals.

26 Apr 2011

March of Dimes honors Whitehead Institute Director for Developmental Biology work

Whitehead Institute Director David Page has been named a recipient of the 2011 March of Dimes Prize in Developmental Biology. The prize honors Page's groundbreaking body of research on the human Y chromosome.

22 Apr 2011

NCI, ASH, AMEH join to improve care for patients with AML

A workshop being held today will serve as the launch of a unique project that unites the American Society of Hematology, the Agrupaci-n Mexicana para el Estudio de la Hematolog-a, and the National Cancer Institute in pursuit of a common goal: improving the care of patients with acute myeloid leukemia.

11 Apr 2011

Elsevier announces title change for Cancer Genetics and Cytogenetics journal

Elsevier, the world's leading publisher of scientific, technical and medical information, announced today that its highly respected Cancer Genetics and Cytogenetics journal is changing its title to Cancer Genetics and has named Dr. Jaclyn A. Biegel as editor-in-chief.

6 Dec 2010

Telik announces positive results from Phase 2 trial of ezatiostat in patients with MDS

Telik, Inc. today announced positive results from a Phase 2 multicenter trial of oral ezatiostat hydrochloride (TELINTRA, TLK199) in patients with an International Prognostic System Score of low to intermediate-1 risk myelodysplastic syndrome.

6 Dec 2010

IRIS announces product acquisition from BioMicro Systems

IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and a provider of high value personalized medicine products and testing services, announced today that it has acquired the assets of a multi-purpose, bench-top instrument platform for automating highly repetitive, manual laboratory protocols for (F)ISH (fluorescence in-situ hybridization) testing and other slide-based cytogenetic applications.

30 Nov 2010

MLL purchases Access Array, EP1 Systems for high-throughput deep-resequencing analysis

Fluidigm Corporation announced today that MLL Munich Leukemia Laboratory has purchased Access Array and EP1 Systems. The Access Array System is being used in combination with Roche's 454 GS FLX and GS Junior sequencing instruments, enabling high-throughput targeted deep-resequencing analyses.

16 Nov 2010

Arrayit sells third advanced microarray manufacturing system to UT Southwestern

Arrayit Corporation announced today that it has sold a third advanced microarray manufacturing system to the University of Texas Southwestern Medical Center at Dallas. The NanoPrint LM60 Microarrayer equipped with Arrayit's Patented Microarray Manufacturing Technology (US Patent 6,101,946) is a computer-driven robotic microarray manufacturing system that enables the screening of 1.5 million lead therapeutic compounds per run, and the NanoPrint LM210 enables more than 5 million.

2 Nov 2010

Clearstone Central Laboratories announces strategic global collaboration with LabCorp

Clearstone Central Laboratories, a leading provider of central laboratory services for late-stage clinical trials, announced today a global collaboration with Laboratory Corporation of America® Holdings through its Esoterix Clinical Trials Services division, providing clients with seamless access to CAP-accredited laboratories across both organizations in Belgium, Canada, China, France, Singapore and the United States.

13 Aug 2010

Eisai reports preliminary results from Dacogen for Injection Phase III study in AML

Eisai Inc. announced today preliminary results from a randomized Phase III clinical trial of Dacogen® (decitabine) for Injection versus either a low-dose chemotherapy agent or supportive care in elderly patients with acute myeloid leukemia (AML), a life-threatening cancer of the blood that generally occurs in older adults.

1 Jul 2010

SuperGen encouraged by Eisai's intent to file Dacogen sNDA for new indication

SuperGen, Inc., a pharmaceutical company dedicated to the discovery and development of novel cancer therapies, announced that Eisai Inc. today released information regarding a randomized Phase III clinical trial of Dacogen® (decitabine) for Injection in elderly patients with acute myeloid leukemia (AML). The comparator in this trial was low-dose cytarabine, a chemotherapy agent, or supportive care.

30 Jun 2010